Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Objective Response Rate (ORR)
The data indicate the activity and tolerability of savolitinib in a subgroup of patients with Papillary Renal Cell Carcinoma (PRCC) (c-Met m). Moreover, the molecular characterization of MET status proved to be a more accurate predictor of response to savolitinib than classification based on pathology. These findings support further investigation of savolitinib in Papillary Renal Cell Carcinoma (PRCC) (c-Met m)
###…